Sinovac Biotech Ltd. Files August 2024 6-K Report
Ticker: SVA · Form: 6-K · Filed: Aug 16, 2024
Sentiment: neutral
Topics: regulatory-filing, 6-K
TL;DR
Sinovac Biotech filed its August 6-K, standard update, CFO Nan Wang signed off.
AI Summary
Sinovac Biotech Ltd. filed a Form 6-K on August 16, 2024, to report its activities for the month of August 2024. The filing includes a signature by Nan Wang, Chief Financial Officer, dated August 16, 2024, and an exhibit index. The company is incorporated in B9 and its fiscal year ends on December 31.
Why It Matters
This filing provides routine updates from Sinovac Biotech Ltd. to the SEC, offering transparency on its ongoing operations and regulatory compliance for the period.
Risk Assessment
Risk Level: low — This is a routine 6-K filing, which typically contains updates on company activities and does not usually involve significant new financial or strategic information.
Key Players & Entities
- Sinovac Biotech Ltd. (company) — Registrant
- Nan Wang (person) — Chief Financial Officer
- August 16, 2024 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer may be required to make public in its home country, to the SEC.
Who signed this specific Form 6-K filing for Sinovac Biotech Ltd.?
Nan Wang, the Chief Financial Officer, signed the Form 6-K filing on behalf of Sinovac Biotech Ltd.
What is the filing date of this report?
The filing date of this report is August 16, 2024.
What is Sinovac Biotech Ltd.'s principal executive office address?
Sinovac Biotech Ltd.'s principal executive office is located at No. 39 Shangdi Xi Rd, Haidian District, Beijing 100085, People's Republic of China.
What is Sinovac Biotech Ltd.'s fiscal year end?
Sinovac Biotech Ltd.'s fiscal year ends on December 31.
Filing Stats: 140 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-08-16 16:15:10
Filing Documents
- tm2421894d1_6k.htm (6-K) — 9KB
- tm2421894d1_ex99-1.htm (EX-99.1) — 217KB
- 0001104659-24-090514.txt ( ) — 227KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 00 1-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SINOVAC BIOTECH LTD. By: /s/ Nan Wang Name: Nan Wang Title: Chief Financial Officer Date: August 16, 2024 Exhibit Index Exhibit 99.1Press Release